BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 6168228)

  • 1. The interaction of protein-bound heparin and antithrombin III.
    Shanberge JN; Sridhar CN
    Ann N Y Acad Sci; 1981; 370():708-13. PubMed ID: 6168228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fate of thrombin and thrombin-antithrombin-III complex adsorbed to a heparinized biomaterial: analysis of the enzyme-inhibitor complexes displaced by plasma.
    Hatton MW; Rollason G; Sefton MV
    Thromb Haemost; 1983 Dec; 50(4):873-7. PubMed ID: 6198746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of protamine sulfate on antithrombin III activity.
    Matsuo T; Shanberge JN; Matsuo O
    Clin Chim Acta; 1983 Jul; 131(3):233-8. PubMed ID: 6883717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dependence of antithrombin III and thrombin binding stoichiometries and catalytic activity on the molecular weight of affinity-purified heparin.
    Nesheim M; Blackburn MN; Lawler CM; Mann KG
    J Biol Chem; 1986 Mar; 261(7):3214-21. PubMed ID: 3949769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respective roles of antithrombin III and alpha 2 macroglobulin in thrombin inactivation.
    Fischer AM; Tapon-Bretaudiere J; Bros A; Josso F
    Thromb Haemost; 1981 Feb; 45(1):51-4. PubMed ID: 6166063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interactions between antithrombin III, thrombin and surface immobilized heparin.
    van Delden CJ; Engbers GH; Feijen J
    J Biomater Sci Polym Ed; 1996; 7(11):989-1004. PubMed ID: 8858487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A study of antithrombin systems during heparin therapy].
    Boneu B; Immaculato F; Sie P; Caranobe C; Chamontin B; Guittard J
    Nouv Presse Med; 1982 Oct; 11(41):3043-6. PubMed ID: 6183640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
    Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
    J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of thrombin with antithrombin III and alpha macroglobulin in the plasma.
    Takada A; Koide T; Takada Y
    Thromb Res; 1979; 16(1-2):59-68. PubMed ID: 92072
    [No Abstract]   [Full Text] [Related]  

  • 10. In vivo catabolism of alpha 1-proteinase inhibitor-trypsin, antithrombin III-thrombin and alpha 2-macroglobulin-methylamine.
    Fuchs HE; Shifman MA; Pizzo SV
    Biochim Biophys Acta; 1982 May; 716(2):151-7. PubMed ID: 6178438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic analysis of various heparin fractions and heparin substitutes in the thrombin inhibition reaction.
    Pletcher CH; Cunningham M; Nelsestuen GL
    Biochim Biophys Acta; 1985 Jan; 838(1):106-13. PubMed ID: 2578296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the mechanism of the rate-enhancing effect of heparin on the thrombin-antithrombin III reaction.
    Holmer E; Söderström G; Andersson LO
    Eur J Biochem; 1979 Jan; 93(1):1-5. PubMed ID: 436823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A method to determine the affinity of heparin to thrombin and antithrombin III on equilibrium gel permeation chromatography.
    Oshima G; Uchiyama H; Nagasawa K
    J Biochem; 1984 Oct; 96(4):1033-9. PubMed ID: 6520110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential role of fractionated heparin in antithrombin-III proteolysis.
    Marciniak E
    Blood; 1982 Mar; 59(3):576-81. PubMed ID: 7037067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement by heparin of thrombin-induced antithrombin III proteolysis: its relation to the molecular weight and anticoagulant activity of heparin.
    Marciniak E; Gora-Maslak G
    Thromb Res; 1982 Nov; 28(3):411-21. PubMed ID: 7179225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histidine-rich glycoprotein does not interfere with interactions between antithrombin III and heparin-like compounds on vascular endothelial cells.
    Shimada K; Kawamoto A; Matsubayashi K; Ozawa T
    Blood; 1989 Jan; 73(1):191-3. PubMed ID: 2910359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the kinetic behavior of human and bovine proteins in the heparin-catalyzed antithrombin III/thrombin reaction.
    Cunningham MT; Nelsestuen GL
    Biochim Biophys Acta; 1987 Jan; 911(1):66-70. PubMed ID: 3790599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease specificity and heparin binding and activation of recombinant protease nexin I.
    Evans DL; McGrogan M; Scott RW; Carrell RW
    J Biol Chem; 1991 Nov; 266(33):22307-12. PubMed ID: 1939253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of thrombin to thrombomodulin accelerates inhibition of the enzyme by antithrombin III. Evidence for a heparin-independent mechanism.
    Preissner KT; Delvos U; Müller-Berghaus G
    Biochemistry; 1987 May; 26(9):2521-8. PubMed ID: 3038185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.